3-iodo-alpha-methyltyrosine has been researched along with Colonic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, T; Iwamura, Y; Kawai, K; Kobayashi, M; Kotani, T; Kubota, N; Nakajima, S; Nakazawa, S; Ogura, M; Okudaira, H; Shikano, N; Yamaguchi, N | 1 |
| Ishikawa, N; Iwamura, Y; Kawai, K; Kotani, T; Kubota, N; Nakajima, S; Nishii, R; Ogura, M; Shikano, N; Yamaguchi, N; Yoshimoto, M | 1 |
2 other study(ies) available for 3-iodo-alpha-methyltyrosine and Colonic Neoplasms
| Article | Year |
|---|---|
Uptake of 3-[125I]iodo-alpha-methyl-L-tyrosine into colon cancer DLD-1 cells: characterization and inhibitory effect of natural amino acids and amino acid-like drugs.
Topics: Amino Acid Transport Systems; Amino Acids; Biological Transport; Cell Line, Tumor; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Methyltyrosines; Structure-Activity Relationship | 2010 |
Pharmacokinetics of 3-[125I]iodo-alpha-methyl-L-tyrosine, a tumor imaging agent, after probenecid loading in mice implanted with colon cancer DLD-1 cells.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Kidney; Male; Metabolic Clearance Rate; Methyltyrosines; Mice; Organ Specificity; Probenecid; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution; Uricosuric Agents | 2007 |